Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
84.54(c) 83.89(c) 84.51(c) 84.26(c) 83.81(c) Last
1 109 215 1 309 351 1 262 190 1 645 724 2 205 530 Volume
+1.12% -0.77% +0.74% -0.30% -0.53% Change
More quotes
Financials (€)
Sales 2017 36 177 M
EBIT 2017 9 601 M
Net income 2017 8 158 M
Debt 2017 4 345 M
Yield 2017 3,61%
Sales 2018 36 905 M
EBIT 2018 9 666 M
Net income 2018 5 816 M
Debt 2018 3 780 M
Yield 2018 3,72%
P/E ratio 2017 12,85
P/E ratio 2018 17,48
EV / Sales2017 3,05x
EV / Sales2018 2,97x
Capitalization 106 B
More Financials
Company
Sanofi engages in the research, production and distribution of pharmaceutical products.It operates through the following business segments: Pharmaceuticals, Human Vaccines, and Animal Health.The Pharmaceuticals segment includes research, development, production and sales activities relating to... 
Sector
Pharmaceuticals
Calendar
11/02 | 07:30amEarnings Release
More about the company
Surperformance© ratings of Sanofi
Trading Rating : Investor Rating :
More Ratings
Latest news on SANOFI
10/20 PEREGRINE PHARMACEUTICALS : Pharma (PPHM) Appoints Mark Bamforth to Board
10/20 PEREGRINE PHARMACEUTICALS : Announces Appointment of Mark R. Bamforth to Board o..
10/19 SANOFI : Pasteur and VaxServe’s Lackawanna County Community Fundraiser Ma..
10/19 SANOFI : - More than 30 Presentations of New Investigational Data from Sanofi : ..
10/18 SANOFI : earmarks 170m for new French vaccines facility
10/18 SANOFI SA (ADR)(NYSE : SNY), Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Dupixen..
10/18 REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Phase 2 Study Results f..
10/18 SANOFI : and Regeneron Announce Positive Phase 2 Study Results for Dupilumab
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17 AIMMUNE THERAPEUTICS : Announces Clinical Collaboration to Study AR101 with Rege..
More news
Sector news : Pharmaceuticals - NEC
10/21 JOHNSON & JOHNSON : California judge tosses $417 million talc cancer verdict aga..
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/20DJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on SANOFI 
SANOFI - 08/14
A support level that should be taken advantage of
BUY
SANOFI - 07/18
Back on an important level
BUY
More Strategies
Latest Tweets
10/20Stock Performance Review on Drug Makers Industry -- Pfizer, Sanofi, Heron The.. 
10/20Sanofi : Stock Performance Review on Drug Makers Industry -- Pfizer, Sanofi, .. 
10/20Regeneron Pharmaceuticals, Inc. $REGN Earns Hold Rating from J P Morgan Chase.. 
10/19Lord Abbett & CO. LLC Purchases Shares of 105,736 Regeneron Pharmaceutica.. 
10/19Regeneron Pharmaceuticals, Inc. $REGN Earns Buy Rating from Canaccord Genuity.. 
More tweets
Qtime:210
News from SeekingAlpha
10/20 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/18 HEALTHCARE DOGFIGHT : Owens & Minor Edges GlaxoSmithKline As Top Broker Pick For..
10/17 The Medicines Company May Not Be The Best Investment In 2017
10/16 Aimmune teams up with Regeneron and Sanofi on AR101 and Dupixent in patients ..
10/16 MANNKIND CORPORATION : Can Afrezza Improved Labeling Fuel A Successful Comeback?
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Average target price 86,7 €
Spread / Average Target 3,4%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI8.99%124 704
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223